DL-Cycloserine
Based on 1 Customer Validation
DL-Cycloserine is an orally active aminotransferase inhibitor. DL-Cycloserine exhibits completely opposite effects on the activity of monoamine oxidase in different tissues. DL-Cycloserine can be used for the research of pulmonary tuberculosis, psychosomatic diseases, and depressive states.
For research use only. We do not sell to patients.
- CAS No.: 68-39-3
- Formula: C3H6N2O2
- Molecular Weight:102.09
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
DL-Cycloserine (0.4-4 mM) significantly inhibits MAO activity in 33% rat liver homogenate and significantly stimulates MAO activity in 50% rat brain homogenate at the same concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
DL-Cycloserine (350-700 mg/kg; p.o.; single dose) significantly suppresses Tryptamine (HY-B2132)-induced convulsions in H Rosice mice[1].
DL-Cycloserine (350-700 mg/kg; p.o.; single dose) significantly blocks Reserpine (HY-N0480)-induced eyelid ptosis in female H Rosice mice[1].
DL-Cycloserine (175 mg/kg; p.o.; single dose) induces sedation in female H Rosice mice, following an initial short excitation phase, causing 100% of mice to fail the rotating-rod test by 90 minute[1].
DL-Cycloserine (87.5-350 mg/kg; p.o.; single dose) significantly potentiates thiopental anaesthesia in female H Rosice mice, and induces hypothermia[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (150-180 g)[3]
-
Dosage:2000 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced liver MAO activity to approximately 80% of control levels (p < 0.001).
Increased brain MAO activity to approximately 135% of control levels (p < 0.05).
-
Animal Model:H Rosice (18-23 g)[3]
-
Dosage:350 mg/kg; 700 mg/kg
-
Administration:p.o.; single dose
-
Result:Significantly reduced Tryptamine-induced convulsion intensity at 350 mg/kg (statistically significant vs. controls).
Significantly reduced tryptamine-induced convulsion intensity at 700 mg/kg (statistically significant vs. controls).
-
Animal Model:H Rosice (female, 18-23 g)[3]
-
Dosage:350 mg/kg; 700 mg/kg
-
Administration:p.o.; single dose
-
Result:Significantly blocked reserpine-induced ptosis at 350 mg/kg when administered simultaneously with Reserpine (statistically significant vs. controls).
Exerted equally significant blocking effect at 700 mg/kg when administered simultaneously with Reserpine.
Showed a small but significant blocking effect at 350 mg/kg when administered 2 hours after Reserpine.
Exerted a stronger significant blocking effect at 700 mg/kg when administered 2 hours after Reserpine.
-
Animal Model:H Rosice (female, 18-23 g)[3]
-
Dosage:175 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced an initial short excitation phase, followed by a sedative effect.
Increased the percentage of mice unable to balance on the rotating rod to 100% by 90 minutes post-administration, with the sedative effect persisting through 180 minutes.
-
Animal Model:H Rosice (female, 18-23 g)[3]
-
Dosage:87.5 mg/kg; 175 mg/kg; 350 mg/kg
-
Administration:p.o.; single dose
-
Result:Potentiated thiopental anaesthesia with an anaesthesia index of approximately 9 at 1 hour and 16 at 2 hours post-administration at 175 mg/kg (both statistically significant vs. controls).
Induced a decline in body temperature at 87.5 mg/kg, 175 mg/kg, and 350 mg/kg.
Chemical Information
-
CAS No. 68-39-3
-
Appearance Solid
-
Molecular Weight 102.09
-
Formula C3H6N2O2
-
SMILES
O=C1NOCC1N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- DL-Cycloserine
- 68-39-3
- Aminotransferases (Transaminases)
- Monoamine Oxidase
- pulmonary tuberculosis
- psychosomatic diseases
- depressive states
- psychotic states
- monoamine oxidase
- Wistar rats
- H Rosice mice
- cytosolic aspartate aminotransferase
- mitochondrial aspartate aminotransferase
- malate-aspartate shuttle
- Inhibitor
- inhibitor
- inhibit